Deal Announcements

MabVax Therapeutics Lands $8 Million Series A

Monday, March 24, 2008 5:39:00 AM PDT | VentureDeal Staff

SAN DIEGO, CA -- Drug discovery company MabVax Therapeutics Inc. announced the completion of its first round of venture capital financing, receiving $8 million from GBP Capital.

MabVax is focused on developing immunotherapies for the treatment of cancer.  The company's work is based on the research of Dr. Phil Livingston and colleagues who have developed monovalent cancer vaccines against ten distinct antigenic targets on various types of cancer cells.

The company is beginning to create a pipeline of polyvalent vaccines and fully human monoclonal antibodies to address cancers including small cell lung cancer, sarcoma and melanoma.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin

PCI - Level1